Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose–Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data

Furihata, Kei; Tsuchikawa, Masaru; Miwa, Takaki; Naito, Yuji; Oba, Koji; Sakagami, Masafumi

doi:10.3390/nu12041128

Cited by 6 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Supplementary zinc intakes would significantly level up serum zinc concentration in the general population ( 41 ) and decrease the incidence of childhood zinc deficiency by 63% (RR: 0.37, 95% CI: 0.22, 0.62) ( 16 ). For adults specifically, the zinc supplemented group though did help improve serum zinc concentration by 0.43 μmol/L, the negative value of the lower limit of the effect size manifested that there is a chance that zinc supplementation had no effect ( 37 ).…”

Section: Resultsmentioning

confidence: 99%

“…A meta-analysis containing five studies found that daily zinc supplements may improve maternal zinc concentrations although a lower limit just crossed the no-effect line (MD: 0.43 μmol/L, 95% CI: −0.04, 0.89) ( 37 ). In the general population, Furihata pointed out that overall zinc supplementation would elevate the serum zinc level by an average number of 9.08 μg/dL (95% CI: 5.46, 12.70) from baseline ( 41 ). Subgroup analysis also supported this impact.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Zinc Intakes and Health Outcomes: An Umbrella Review

Cao

Huang

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

It is widely accepted that the zinc element is crucial in human beings. Zinc has gained more attention during the COVID-19 pandemic due to its utilization for the treatment and prevention of respiratory tract infections. However, some studies also pointed out that zinc intake might cause unwanted side effects and even be dangerous when overdosed. To reveal the relationship between zinc intake and health outcomes, we performed an umbrella review from human studies. In total, the umbrella review included 43 articles and identified 11 outcomes for dietary zinc intake and 86 outcomes for supplementary zinc intake. Dietary zinc intake in the highest dose would decrease the risk of overall and specific digestive tract cancers, depression, and type 2 diabetes mellitus (T2DM) in adults. Supplementary zinc consumption in adults was linked to an improvement of depression, antioxidant capacity and sperm quality, higher serum zinc concentration, and lower concentration of inflammatory markers. Zinc supplementation in children would reduce the incidence of diarrhea and pneumonia, improve zinc deficiency and boost growth. However, zinc might not decrease all-cause mortality in adults or the in-hospital mortality of COVID-19. And better maternal and neonatal outcomes may not derive from pregnant women who consumed higher or lower doses of zinc supplementation (>20 mg/day and <20 mg/day, respectively). Dose-response analyses revealed that a daily 5 mg increment of zinc would lower the risk of colorectal and esophageal cancer, whereas a large dose of zinc supplementation (daily 100 mg) showed no benefit in reducing prostate cancer risk.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Zinc Intakes and Health Outcomes: An Umbrella Review

Cao

Huang

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…In their systematic review of randomized clinical trials, Furihata et al 33 reported that serum zinc concentration increases after oral administration of PZ (75‐300 mg/day) in a dose‐dependent manner. Of note, this increase is not significant at a dose of 75 mg/day (2.60 μg/dL, P = .52), but is significant at doses of 150 mg/day (9.07 μg/dL, P < .001) and 300 mg/day (23.05 μg/dL, P = .001).…”

Section: Discussionmentioning

confidence: 99%

“…PZ is highly safe and no specific AEs were observed in the present study. In their systematic review of randomized clinical trials, Furihata et al 33 reported that serum zinc concentration increases after oral administration of PZ (75-300 mg/day) in a dose-dependent manner.…”

Section: Discussionmentioning

confidence: 99%

Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi‐institutional randomized controlled trial

Kitagawa

Kobayashi

Nagata

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

Oral mucositis is a common and distressing complication in patients receiving high‐dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT). We reported previously in a single‐center retrospective analysis that zinc‐L‐carnosine (polaprezinc [PZ]) reduced the incidence of oral mucositis associated with HSCT. To verify the accuracy of the prophylactic effect of PZ against oral mucositis, we carried out a multi‐institutional prospective randomized controlled study. Patients were randomly allocated to either the prevention group, in which PZ lozenge treatment was started before chemotherapy, or the control group, in which administration of PZ lozenges was initiated immediately after the onset of Grade 2 oral mucositis. Oral mucositis was evaluated daily from the start of chemotherapy to 35 days after transplantation. A total of 91 patients were enrolled, and 88 patients (47 in the control group and 41 in the prevention group) were eligible for data analysis. The incidence of Grade ≥2 but not Grade ≥3 oral mucositis was significantly reduced in the prevention group compared to the control group (44.7% in control group vs 22.0% in the prevention group, P = .025). There were no significant differences in the incidence rates of other adverse events or the rate of engraftment (95.6% vs 97.2%, P = .693) between the two groups. These findings suggest that PZ lozenge is effective for prophylaxis against Grade ≥2 oral mucositis associated with chemotherapy in patients undergoing HSCT without any influence on the HSCT outcome.

show abstract

“…Moreover, polaprezinc (PZN), a zinc-L-carnosine complex ( Figure 1 ) [ 23 ], has promising properties as an antioxidant promoting ulcer healing and mucosal protective agent to counteract various clinical conditions in animals and human studies [ 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. Furthermore, PZN can function by ameliorating inflammation [ 33 ], preventing apoptosis [ 34 ], and protecting tight junctions.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

et al. 2022

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is the most prevalent etiology of gastritis worldwide. H. pylori management depends mainly on antibiotics, especially the triple therapy formed of clarithromycin, amoxicillin, and proton pump inhibitors. Lately, many antibiotic-resistant strains have emerged, leading to a decrease in the eradication rates of H. pylori. Polaprezinc (PZN), a mucosal protective zinc-L-carnosine complex, may be a non-antibiotic agent to treat H. pylori without the risk of resistance. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of a PZN-based regimen for the eradication of H. pylori. This study used a systematic review and meta-analysis synthesizing randomized controlled trials (RCTs) from WOS, SCOPUS, EMBASE, PubMed, and Google Scholar until 25 July 2022. We used the odds ratio (OR) for dichotomous outcomes presented with the corresponding 95% confidence interval (CI). We registered our protocol in PROSPERO with ID: CRD42022349231. We included 3 trials with a total of 396 participants who were randomized to either PZN plus triple therapy (n = 199) or triple therapy alone (control) (n = 197). Pooled OR found a statistical difference favoring the PZN arm in the intention to treat and per protocol H. pylori eradication rates (OR: 2.01 with 95% CI [1.27, 3.21], p = 0.003) and (OR: 2.65 with 95% CI [1.55, 4.54], p = 0.0004), respectively. We found no statistical difference between the two groups regarding the total adverse events (OR: 1.06 with 95% CI [0.55, 2.06], p = 0.85). PZN, when added to the triple therapy, yielded a better effect concerning the eradication rates of H. pylori with no difference in adverse event rates, and thus can be considered a valuable adjuvant for the management of H. pylori. However, the evidence is still scarce, and larger trials are needed to confirm or refute our findings.

show abstract

Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose–Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data

Cited by 6 publications

References 27 publications

Zinc Intakes and Health Outcomes: An Umbrella Review

Zinc Intakes and Health Outcomes: An Umbrella Review

Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi‐institutional randomized controlled trial

Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About